SMS Pharmaceuticals Limited

NSE SMSPHARMA.NS

SMS Pharmaceuticals Limited EBITDA for the year ending March 31, 2024: USD 14.42 M

SMS Pharmaceuticals Limited EBITDA is USD 14.42 M for the year ending March 31, 2024, a 99.50% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

SMS Pharmaceuticals Limited EBITDA for the year ending March 31, 2023 was USD 7.23 M, a -54.10% change year over year.
SMS Pharmaceuticals Limited EBITDA for the year ending March 31, 2022 was USD 15.74 M, a -7.47% change year over year.
SMS Pharmaceuticals Limited EBITDA for the year ending March 31, 2021 was USD 17.01 M, a 50.76% change year over year.
SMS Pharmaceuticals Limited EBITDA for the year ending March 31, 2020 was USD 11.28 M, a -16.13% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NSE: SMSPHARMA.NS

SMS Pharmaceuticals Limited

CEO	Mr. Ramesh Babu Potluri
IPO Date	Feb. 28, 2007
Location	India
Headquarters	Plot No. 72
Employees	1,197
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Plastics

Description

SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral APIs. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.

Key trends

Past 5 years